ADIL Adial Pharmaceuticals, Inc.

NASDAQ
$3.98

Adial Pharmaceuticals, Inc. (ADIL) is expected to report earnings on November 13, 2026, before the market open. The stock has had a Post-Earnings Announcement Drift (PEAD) of -3.2% since its last earnings release on August 14, 2026.

Adial Pharmaceuticals, Inc. Reported Earnings
Earnings Date
3rd Quarter, Sep 2026
Nov 13
Friday · 8:30 AM ET
Earnings Whisper
-
vs -
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.87

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.

Sector

Healthcare

Industry

Biotechnology